Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Former Sen. Kyrsten Sinema (I-Ariz.) is joining the Hogan Lovells’s global regulatory and intellectual property team as a senior adviser, the lobbying firm announced Monday. “Senator Sinema ...

Former Sen. Kyrsten Sinema has a new role at the law firm Hogan Lovells, where she’ll use her experience as a Capitol Hill lawmaker to help clients navigate “regulatory and political change.” ...

Washington’s revolving door between lawmakers and its lobbying class saw former Sen. Kyrsten Sinema (I-AZ) emerge with a new job on Monday. The onetime Democrat, attorney, and the first out ...

SINEMA HEADS DOWNTOWN: Former Sen. Kyrsten Sinema, the centrist dealmaker who wielded virtually unilateral veto power over the Biden administration’s legislative agenda, has landed on K Street ...

Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Former U.S. Senator for Arizona, Kyrsten Sinema, is joining a law and lobbying firm. The firm, Hogan Lovells, says the Democrat turned independent will serve as senior counsel in the organization ...